Hudson Bay Capital Management LP Buys 13,466 Shares of AbbVie Inc. $ABBV

Hudson Bay Capital Management LP increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 24.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 69,352 shares of the company’s stock after acquiring an additional 13,466 shares during the period. Hudson Bay Capital Management LP’s holdings in AbbVie were worth $16,058,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of ABBV. Ellenbecker Investment Group increased its position in shares of AbbVie by 0.8% during the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock worth $1,235,000 after purchasing an additional 44 shares during the last quarter. Security National Bank of Sioux City Iowa IA boosted its holdings in shares of AbbVie by 0.3% in the 3rd quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock valued at $3,562,000 after buying an additional 45 shares during the last quarter. Matthew Goff Investment Advisor LLC boosted its holdings in shares of AbbVie by 0.3% in the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock valued at $4,066,000 after buying an additional 45 shares during the last quarter. Centennial Wealth Advisory LLC grew its stake in shares of AbbVie by 2.2% in the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock valued at $484,000 after buying an additional 45 shares in the last quarter. Finally, Willner & Heller LLC increased its holdings in AbbVie by 0.6% during the third quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock worth $1,759,000 after buying an additional 46 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Price Performance

ABBV stock opened at $206.32 on Friday. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The stock has a market cap of $364.80 billion, a price-to-earnings ratio of 87.42, a price-to-earnings-growth ratio of 0.72 and a beta of 0.34. The company has a fifty day moving average price of $223.41 and a two-hundred day moving average price of $224.71.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company’s revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the firm earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.4%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio is currently 293.22%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on ABBV shares. Barclays started coverage on shares of AbbVie in a research report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price target on the stock. Piper Sandler boosted their price objective on shares of AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. William Blair reaffirmed an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Berenberg Bank set a $275.00 target price on shares of AbbVie in a research note on Tuesday, January 20th. Finally, HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and lifted their price target for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $253.15.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) released new global consumer research and updated educational programs that could support its aesthetics franchise and long‑term revenue diversification. Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments
• Neutral Sentiment: Independent valuation and market‑commentary pieces highlight a recent share‑price pullback and renewed debate over AbbVie’s near‑term multiple; these analyses may lead to more analyst revisions but are not a direct operational hit. Assessing AbbVie (ABBV) Valuation After The Recent Share Price Pullback
• Negative Sentiment: FDA approved J&J’s Icotyde, the first oral IL‑23 inhibitor, creating direct competition for Skyrizi; analysts and articles warn Icotyde could capture significant market share because of oral dosing convenience, pressuring AbbVie’s key growth driver. J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections
• Negative Sentiment: Market reaction: multiple outlets report a ~5% intraday drop and continued underperformance vs. peers as investors price in Icotyde competition and reassess AbbVie’s growth outlook. Elevated volume suggests defensive positioning. ABBV Stock Slides 5%: Is J&J’s Icotyde a Threat to Skyrizi?
• Negative Sentiment: Breckenridge launched a generic version of Savella (milnacipran), which introduces additional generic competition in a product AbbVie previously marketed—incremental revenue headwind for that niche pain product. Breckenridge announces launch of Milnacipran HCl Tablets, generic equivalent of Savella®

Insider Activity at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.25% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.